Company research / YARW

Yarrow Bioscience, Inc. (YARW)

CIK 0001566044 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Yarrow Bioscience, Inc. reported revenue of $570.0K. Revenue grew 13.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $482.0K.

Key ratios (year ended 2025-12-31)

n/m
Operating margin
n/m
Net margin
-95.4%
Return on year-end equity
13.8%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-18, first reflected in a filing dated 2023-03-14; 1-for-50, first reflected in a filing dated 2026-08-13. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$482.0K$570.0K$501.0K$424.0K$477.0K$931.0K$20.99M$443.0K$3.60Mn/an/a
Cost of Revenuen/an/an/an/an/a$3.35M$1.39M$0$0n/an/a
Gross Profit (computed)n/an/an/an/an/a-$2.42M$19.60Mn/an/an/an/a
R&D Expense$9.84M$19.24M$30.95M$16.31M$18.39M$19.54M$43.53M$51.20M$64.47M$29.01M$11.26M
Operating Income-$19.93M-$29.75M-$43.64M-$29.26M-$34.30M-$38.91M-$252.55M-$95.87M-$74.89M-$29.59M-$14.33M
Depreciation & Amortization$23.0K$23.0K$4.0K$0$72.0K$109.0K$341.0K$350.0K$319.0Kn/an/a
EBITDA-$19.91M-$29.73M-$43.63M-$29.26M-$34.22M-$38.80M-$252.21M-$95.52M-$74.57Mn/an/a
Net Income-$18.71M-$26.48M-$39.83M-$28.45M-$23.21M-$73.33M-$255.57M-$95.18M-$74.16M-$29.08M-$14.07M
EPS (Diluted)n/a-$0.62-$0.93-$2.78-$7.28-$25.64$7.88n/an/an/an/a
Total Assets$23.60M$30.16M$66.91M$97.69M$40.76M$67.05M$93.74M$81.16M$139.93M$66.87M$42.05M
Total Liabilities$1.54M$2.40M$14.82M$8.95M$9.35M$18.41M$56.25M$63.58M$9.55M$14.57M$12.49M
Long-Term Debt$0$0$0$0$0$0n/an/an/an/an/a
Shareholders' Equity$22.06M$27.77M$52.09M$88.73M$31.20M$48.64M$37.49M$17.57M$92.18M-$57.03M-$29.44M
Cash & Equivalents$22.93M$24.03M$19.93M$30.62M$30.91M$42.25M$57.56M$43.76M$27.87M$10.21M$4.03M
Operating Cash Flow-$16.93M-$33.12M-$33.97M-$25.34M-$29.20M-$56.37M-$137.08M-$73.39M-$68.66M-$28.22M-$2.27M
Capital Expendituresn/a$0$117.0K$0n/an/an/an/an/an/an/a
Free Cash Flown/a-$33.12M-$34.09M-$25.34Mn/an/an/an/an/an/an/a
Shares Outstanding668.3K33.32M14.83M14.10M3.23M2.98M43.21M9.12M23.23M5.30M5.28M
Weighted Average Diluted Sharesn/a42.77M42.59M10.27M3.19M2.86M32.42Mn/an/an/an/a
EPS (Basic)n/a-$0.62-$0.93-$2.78-$7.28-$25.64$7.88n/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView